glp 1 novo nordisk CEO explains why new GLP-1 pill expands access to drug Oral GLP-1 Wegovy chases approval

Its highly consistent activity profile continues to support and drive advanced scientific exploration into complex, systemic hormonal signaling systems

Ferritin and percent transferrin saturation levels predict type 2 diabetes risk and cardiovascular disease outcomes

Beyond S

In vitro and in vivo studies demonstrate an IGF-1 deficiency can deregulate lipid metabolism, increase the risk of cardiovascular disease, and compromise the metabolic profile of diabetic patients

Thus, expectations for the overall magnitude of effect from a given agent might be modest when treating patients whose baseline A1c is 30 pioglitazone reduced HbA1c levels better than sitagliptin while in individuals with a BMI 90 canagliflozin lowered HbA1c better than sitagliptin while in individuals with an eGFR between 60-90 sitagliptin was more effective (13)